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Aim: Evidence suggests beneficial metabolic effects of the nonapeptide hormone, arginine 
vasopressin (AVP), on metabolism, as also observed recently with the closely related 
oxytocin peptide.  
Materials and Methods: In the current study we have exchanged selected amino acids at 
position 3 and 8 of AVP, namely phenylalanine and arginine, with those of oxytocin to 
generate novel analogues with altered receptor selectivity. Secondary modification by N-
terminal acetylation was used to impart stability to circulating endopeptidases. Analogues 
were screened for degradation, bioactivity in rodent/human clonal beta-cells and primary 
murine islets together evaluation of receptor activation profile. 
Results: Analogue Ac3IV, which lacked effects at V2 receptors responsible for modulation 
of fluid balance, was selected as the lead compound for assessment of antidiabetic efficacy in 
high fat fed (HFF) mice. Twice daily administration of Ac3IV, or the gold-standard control 
exendin-4, for 22 days reduced energy intake as well as body weight and fat content. Both 
interventions decreased circulating glucose levels, enhanced insulin sensitivity and 
substantially improved glucose tolerance and related insulin secretion in response to an 
intraperitoneal or oral glucose challenge. The peptides decreased total- and increased HDL-
cholesterol, but only Ac3IV decreased LDL-cholesterol, triglyceride and non-fasting 
glucagon concentrations. Elevations of islet and beta cell areas were partially reversed, 
accompanied by suppressed islet cell proliferation, decreased beta-cell apoptosis and, in the 
case of exendin-4, also decreased alpha-cell apoptosis.  
Conclusion: AVP-based therapies that exclusively target V1a and V1b receptors may have 
significant therapeutic potential for the treatment of obesity and related diabetes, that merits 
further clinical exploration. 




The past 15 years have witnessed a substantial increase in the treatment options available for 
type 2 diabetes with the timely introduction of glucagon-like peptide-1 (GLP-1) mimetics, as 
well as dipeptidyl peptidase-4 (DPP-4) and sodium-glucose co-transporter-2 (SGLT-2) 
inhibitors [1]. In particular, the clinical success of GLP-1 mimetics has illustrated the benefit 
of simultaneous activation of multiple physiological pathways by a single peptide entity, 
conferring positive effects on insulin secretion and action, gut motility, appetite and body 
weight as well as cardiovascular and neuronal function [2]. Unimolecular dual or even triple 
acting peptides targeting GLP-1, GIP and glucagon receptors are now being developed to 
modulate multiple receptor sites [3,4]. Other peptides being explored include apelin, peptide 
YY (PYY), cholecystokinin (CCK-8), fibroblast growth factor-21 (FGF-21), oxyntomodulin, 
irisin, obestatin and xenin [5,6]. Given present imperfections in attempts to normalise blood 
glucose and prevent risk of diabetic complications [5], the search continues for other 
naturally occurring peptide hormones with beneficial action profiles that can be structurally 
modified to confer enzyme stability and long duration of action for potential exploitation in 
T2DM therapy [4]. 
Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH) is a 
nonapeptide synthesised in the hypothalamus and secreted by the posterior pituitary gland 
[7]. Although the classically recognised physiological action of AVP is in the regulation of 
fluid balance and cardiovascular function [8], an increasing body of evidence suggests that 
AVP plays an important role in glucose homeostasis and metabolic control [9]. The 
biological effects of AVP are mediated through modulation of three separate GPCRs, namely 
Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2) [10]. Whilst the V2 receptor is responsible for 
the effects of AVP on the kidney and water retention [11], V1a and V1b receptors are 
expressed in metabolically active tissues [10]. Studies in AVP receptor knockout (KO) 
 
 
rodents confirm a role for AVP signalling in metabolism. Thus, plasma glucose levels are 
elevated in V1a receptor KO mice [12] but reduced in V1b KO mice [13]. Mice with double 
V1a and V1b receptor KO present with unaltered circulating glucose levels, but this is 
accompanied by hyperinsulinaemia and glucose intolerance [14]. Furthermore, an inherent 
genetic mutation leading to lack of AVP production in rats results in reduced plasma insulin 
concentrations [15]. Genetic variation in AVP receptor expression in humans is also 
associated with obesity and increased prevalence of diabetes [16,17].  
 In addition, AVP receptors are present on pancreatic islets and their activation directly 
evokes insulin secretion and protects against beta cell loss [18]. AVP is also known to 
stimulate glucagon secretion [19], but AVP-induced insulin release only occurs in the 
presence of high glucose concentrations, whereas effects on glucagon secretion are only 
apparent when glucose levels are low [20]. This represents a physiologically important action 
in the maintenance of glucose homeostasis, linked to prevention of both hyper- and 
hypoglycaemia. Such a biological characteristic is also evident with the incretin hormone GIP 
[5,21], which is now considered to possess bona fide therapeutic promise for diabetes 
[22,23]. Taken together, these observations suggest that AVP may have untapped potential 
for exploitation in the treatment of diabetes and related metabolic disorders. 
Interestingly, AVP has a strikingly similar structure to oxytocin with the two 
nonapeptides only differing at positions 3 and 8, with phenylalanine and arginine in AVP 
being replaced by isoleucine and leucine in oxytocin [24]. Although native oxytocin is best 
known for positive effects on mood and reproductive function [25], enzyme resistant 
analogues have recently been developed and shown to exert notable benefits on body weight, 
glucose homeostasis, lipid metabolism and pancreatic architecture in HFF mice [26,27]. We 
hypothesised that the similarity in structure between the two hormones provides a good 
foundation for the generation of novel and therapeutically interesting peptides that could 
 
 
positively interact with both oxytocin and AVP receptor subtypes. In an attempt to generate 
such compounds, we designed six novel AVP peptides where amino acids at positions 3 and 
8 in AVP were replaced by those of oxytocin (Table 1). We also examined effects of removal 
of the characteristic disulphide bridge plus addition of N terminal acetyl group to impart 
enzyme resistance, as employed previously [27]. 
The AVP analogues were initially screened for enzymatic stability, insulin secretory 
responses in vitro and ex vivo together with receptor activation profile. The lead peptide 
emerging from these studies, namely Ac3IV, which lacked appreciable effects at V2 
receptors, was progressed to antidiabetic efficacy testing in high fat fed (HFF) mice in head-
to-head comparison with the clinically approved GLP-1 mimetic, exenatide. Our results 
suggest that such designer AVP analogues constitute a potentially exciting new drug class 
meriting further exploration for the treatment of obesity and type 2 diabetes. 
 
2. Materials and Methods 
2.1 Peptides  
All peptides (Table 1) were obtained from Synpeptide Co. Ltd. (Shanghai, China) at 95% 
purity. Characterisation of the peptides was carried out in-house by HPLC and MALDI–ToF 
MS, as described previously [28]. Abbreviated names are used for AVP analogues, denoting 
as appropriate, the position and type of amino acid substitutions in AVP (where AVP is 
abbreviated to V), namely 3IV and 8LV, presence of N-acetyl group (abbreviated to Ac) and 
indication of reduced form without disulphide bridge by letter R.   
 
2.2 Plasma stability 
 
 
To establish in vitro stability of the peptides, peptides (10 μg) were incubated with 5 μl of 
overnight (18 h) fasted murine plasma at 37ºC, with degradation profiles acquired using RP-
HPLC and MALDI-ToF, as described previously [29]. 
 
2.3 In vitro and ex vivo insulin secretion  
Rat BRIN BD11 and human 1.1B4 cells were utilised to investigate the influence of test 
peptides on insulin release. The origin and secretory characteristics of these clonal beta-cells 
have been detailed in full elsewhere [30,31]. Insulin secretory activity (20 min) of test peptides 
(10-12 – 10-6 M) at 5.6 and 16.7 mM glucose was determined as previously described [27]. In a 
separate series, BRIN BD11 cells were incubated at 16.7 mM glucose with test peptides (10-6 
M) alone, or in combination with 10-6 M of either a selective oxytocin (L-351,257; Tocris), V1a 
(SR-49059, Sigma-Aldrich), V1b (Nelivaptan; SR -149415, Axon Medchem) or V2 
(Tolvaptan, Sigma-Aldrich) receptor antagonist, and insulin secretion determined as described 
above. Given somewhat unexpected lack of effect of L-351,257 on Ac3IV mediated insulin 
secretion, insulin secretory effects of Ac3IV were examined in INS1 832/13 cells with 
CRISPR-Cas9 induced knockout (KO) of the oxytocin receptor. Full details on the generation 
and characterisation of the KO cell line have previously been reported [27]. For isolated islets 
studies, islets were obtained from male C57BL/6 mice by standard collagenase digestion, as 
described previously [32]. Fresh islets were preincubated for 30 min at 37°C in Krebs–Ringer 
bicarbonate buffer (pH 7.4) supplemented with 10 mM HEPES, 0.1% bovine serum albumin 
and 1.1 mM glucose, prior to conducting insulin secretion studies (n=4) over the following 60 
min. 
  
2.4 Animals  
 
 
Studies were conducted in 20-week old HFF male NIH Swiss mice (Envigo Ltd, UK) 
previously maintained on a high fat diet for 12 weeks (45% fat, 20% protein, 35% 
carbohydrate; percent of total energy 26.15 kJ/g; Dietex International Ltd., Witham, UK; 
catalogue number 824018) to evoke dietary induced obesity-diabetes. All mice were housed 
individually and kept in a temperature-controlled environment (22 ± 2 oC), with a 12 hour 
light/dark cycle. Experiments were carried out in accordance with the UK Animal Scientific 
Procedures Act 1986. All animal studies were approved by the University of Ulster Animal 
Welfare and Ethical Review Body (AWERB). No adverse effects were observed during the in 
vivo procedures.  
 
2.5 In vivo experimental design 
HFF mice were allocated into comparable groups (n=8) based on blood glucose and body 
weight and were administered either saline vehicle (0.9% (w/v) NaCl, i.p.), Ac3IV or 
exendin-4 (both at 25 nmol/kg, bw, i.p.) twice daily for 22 days. This peptide dose was 
chosen based on our previous studies assessing metabolic effects of AVP in mice [18]. An 
additional control group of HFF mice receiving either native AVP or oxytocin was not 
employed due to the short biological half-lives of these peptides [18,27]. Cumulative food 
and fluid intake, body weight, non-fasting glucose and insulin concentrations were monitored 
at regular intervals. At the end of the treatment period, plasma was collected for assessment 
of circulating glucagon and lipids. In addition, i.p. and oral glucose (18 mmol/kg) tolerance 
tests were performed in 18 h fasted mice, with peripheral insulin sensitivity (15 U/kg bw, i.p.) 
examined tests in non-fasted mice, at the end of the study. At termination, body composition 
was assessed by dual energy X-ray absorptiometry (DEXA) scanning using a PIXImus 




2.6 Terminal analyses  
Following completion of DEXA analysis, pancreatic tissues were excised and processed for 
either histological analysis or hormone content. Briefly, pancreatic tissues were divided 
longitudinally with half snap frozen for hormonal content measurement as described 
previously [34], and the other half processed for immunohistochemical analysis using 
standard laboratory methods, as previously described from our laboratory [35].  
 
2.7 Biochemical analysis  
Blood samples were collected from the cut tip on the tail vein of conscious mice. Blood 
glucose was measured immediately using a hand-held Ascencia Contour blood glucose meter 
(Bayer Healthcare, Newbury, Berkshire, UK). For plasma insulin and glucagon, blood was 
collected in chilled fluoride/heparin coated micro-centrifuge tubes (Sarstedt, Numbrecht, 
Germany) and centrifuged using a Beckman micro-centrifuge (Beckman Instruments, 
Galway, Ireland) for 10 minutes at 12,000 rpm. Plasma was separated and stored at -20oC, 
until determination of plasma insulin by radioimmunoassay [36] and glucagon by a 
commercially available ELISA kit (EZGLU-30K, Merck Millipore). Plasma lipid profile was 
assessed by an ILab 650 Clinical Analyser (Instrumentation Laboratory, Warrington, UK). 
 
2.8 Statistical analysis  
Analyses were performed using GraphPad PRISM software (Version 5.0). Values are 
expressed as mean ± S.E.M. Comparative analyses between groups were carried out using a 
One-way ANOVA with Bonferroni’s post hoc test or student's unpaired t-test, as appropriate. 





3.1 Plasma degradation 
AVP was fully degraded by a 4 hour incubation in plasma (Table 1). In addition, oxytocin 
and all non N-terminally acetylated AVP analogues were also degraded by more than 60% 
during the 4 hour incubation (Table 1). N-acetylation of the cysteine residue in 3IV or 3IVR 
generated AVP analogues that were completely stable (Table 1).  
 
3.2 Effects of AVP analogues on in vitro insulin secretion 
Representative dose-dependent insulin secretory responses of native AVP and oxytocin, as 
well as the two enzymatically stable analogues, namely Ac3IV and Ac3IVR, in both cell lines 
are depicted in Figure 1A-D. As expected, AVP induced prominent insulinotropic effects, 
with both AVP analogues also displaying clear dose-dependent actions in each cell line 
(Figure 1A-D). Full concentration-response curves could not be obtained, thus precluding 
calculation of EC50 values, as well as any comment about relative efficacy of these 
compounds in the different cell lines. Nonetheless, clear insulinotropic efficacy of Ac3IV was 
confirmed in murine islets at a concentration of 10-6 M (Figure 1E).  
 
3.3 In vitro receptor activation profile of AVP analogues   
As expected, AVP-induced insulin secretion was strongly linked to activation of oxytocin, 
V1a and V1b receptors, and to a lesser degree with V2 receptors (Table 1). Removal of the 
disulphide bridge in AVP completely abolished activity at V2 receptors (Table 1). 
Interestingly, the insulinotropic activity of 8LV was related to interaction with all oxytocin 
and vasopressin receptors subtypes, and especially V2 receptors (Table 1). Activity at all 
receptors, barring V1b, was dramatically decreased by disulphide bond removal (Table 1). 
Substitution of isoleucine for phenylalanine in AVP represented by 3IV, had minimal impact 
of receptor activation profile in BRIN BD11 cells (Table 1), but removal of the characteristic 
 
 
AVP disulphide bridge, substantially decreased activity at the level of the oxytocin receptor 
and annulled all V2 receptor activity (Table 1). N-terminal acetylation of 3IV, to yield 
Ac3IV, diminished activity at oxytocin receptors, as evidence by the marked reduction in the 
ability of the oxytocin-receptor antagonist L-351,257 to reduce the insulin secretory response 
in BRIN BD11 cells (Table 1). When the disulphide bridge was removed from Ac3IV, 
oxytocin receptor activity was restored but activity at V1b, and particularly V1a, receptors 
reduced (Table 1). Given Ac3IV exhibited pronounced enzymatic stability and good 
insulinotropic efficacy in 1.1B4 cells, oxytocin receptor interaction was also examined in 
INS1 832/13 beta cells with CRISPR-Cas9 induced oxytocin receptor KO to corroborate 
findings with L-351,257. As shown in Figure 1F, insulin secretory effectiveness of Ac3IV 
was significantly (P<0.05) more prominent than AVP in oxytocin receptor KO beta cells.  
 
3.4 Effects of twice daily administration of Ac3IV on body weight, energy intake, fluid 
intake and plasma glucose, insulin and glucagon in HFF mice 
Based on enzymatic stability, impressive in vitro bioactive profile and lack of effect at V2 
receptors which mediate renal actions of AVP, Ac3IV was selected for antidiabetic efficacy 
testing in HFF mice, and compared directly head-to-head against the clinically approved 
GLP-1 mimetic, exendin-4. Twice daily administration of 25 nmol/kg Ac3IV or exendin-4 
resulted in significant (P<0.05 to P<0.001) reductions in body weight (Figure 2A), and 
importantly body fat content (Figure 2B), by day 22 when compared to HFF control mice. 
This was associated with significantly decreased (P<0.05 to P<0.001) cumulative energy 
intake in both treatment groups (Figure 2C). Fluid intake was similar in all groups with a 
small cumulative increase observed after 19 days of Ac3IV treatment (Figure 2D). 
Circulating blood glucose levels were also decreased in all treatment groups, culminating in 
significant (P<0.01) reductions when compared to HFF controls on day 22 (Figure 2E). This 
 
 
was accompanied by reduced overall glucose exposure in exendin-4 and Ac3IV mice during 
the entire treatment period (Figure 2E inset). Corresponding, daily plasma insulin 
concentrations were largely unaltered during the study, but there was a significant decrease 
(P<0.05) in this parameter in both treatment groups on day 16 (Figure 2F), as well as in 
overall insulin levels during the 22 days (Figure 2F inset). Plasma glucagon levels were not 
changed in exendin-4 treated HFF mice, but significantly reduced (P<0.05) by Ac3IV 
treatment (Figure 3A).  
 
3.5 Effects of twice daily administration of Ac3IV on pancreatic hormone content, lipid 
profile and bone mineral density in HFF mice 
Pancreatic insulin content was significantly reduced (P<0.05 to P<0.01) in both treatment 
groups when compared to HFF control mice (Figure 3B), whereas pancreatic glucagon 
content was not altered (Figure 3C). In terms of lipid profile, Ac3IV and exendin-4 therapy 
were both associated with reduced total cholesterol (Figure 3D) and increased HDL-
cholesterol (Figure 3E) levels, but only Ac3IV significantly (P<0.05) decreased LDL-
cholesterol and triglyceride concentrations (Figure 3F,G). Bone mineral density (P<0.01) and 
content (P<0.05) were increased on day 22 in both the HFF treatment groups of mice (Figure 
3H,I).   
 
3.6 Effects of twice daily administration of Ac3IV on glucose tolerance and insulin 
sensitivity in HFF mice 
Administration of exendin-4 twice daily for 22 day significantly (P<0.05 to P<0.01) 
decreased individual and overall blood glucose levels following an i.p. glucose challenge 
(Figure 4A,B). Ac3IV treatment was also associated with significantly (P<0.05) decreased 
glucose 0-120 min AUC values when compared to HFF controls (Figure 4B). In addition, 
 
 
individual glucose-induced insulin concentrations were only increased (P<0.05 – P<0.01) by 
Ac3IV (Figure 4C), with both treatment regimens increasing overall AUC insulin values 
(Figure 4D). In response to an oral glucose challenge, the treatment interventions 
significantly decreased individual (P<0.05 to P<0.001) and overall (P<0.01) blood glucose 
levels when compared to saline controls (Figure 4E,F). There were no changes in plasma 
insulin concentrations at individual timepoints (Figure 4G), but exendin-4 and Ac3IV both 
increased (P<0.01 to P<0.001) 0-120 overall plasma insulin concentrations in response to an 
oral glucose load (Figure 4H). Furthermore, the glucose lowering activity of exogenous 
insulin was significantly increased (P<0.01 to P<0.001) by both treatments on day 22 (Figure 
4I,J), which was  supported by a significant decrease (P<0.01 to P<0.001) in HOMA-IR 
values in these groups of mice when compared to saline treated HFF controls (Figure 4K).  
 
3.7 Effects of twice daily administration of Ac3IV on pancreatic islet morphology in 
HFF mice 
Representation histological images of pancreatic islets stained for insulin and glucagon are 
shown in Figure 5A. High fat feeding was associated with insulin resistance and islet 
expansion, but both exendin-4 and Ac3IV significantly decreased islet and beta-cell areas 
when compared to HFF saline controls (Figure 5B,C), with effects being more prominent in 
Ac3IV treated mice. There was no significant change in alpha-cell area between the groups of 
HFF mice (Figure 5D). Proliferation rates of alpha and beta cells were decreased by both 
exendin-4 and Ac3IV treatment (Figure 5E,F). Apoptotic rates were also examined by co-
staining glucagon or insulin, respectively, with TUNEL dye (Figure 5G,H). Both exendin-4 
and Ac3IV reduced (P<0.01 – P<0.001) beta cell apoptosis rates when compared to saline 
control mice (Figure 5G), with exendin-4 treatment also increasing (P<0.05) the rate of 





The presence of AVP receptors on pancreatic beta-cells, as well as related positive effects of 
AVP on insulin secretion demonstrated many years ago [37], have since been confirmed by 
several laboratories [18,38,39]. AVP also has established satiety actions [40], as well as an 
ability to avert the onset of hypoglycaemia [9]. Indeed, hypothalamic AVP neurons 
regulating glucagon secretion are considered to function as metabolic glucose sensors [41], 
supporting an important role for AVP in glucose homeostasis. Such actions are believed to be 
largely mediated through activation and modulation of V1a and V1b receptor signalling [10]. 
Despite this knowledge, the potential therapeutic utility of AVP has been overlooked to date. 
The reason for this is likely two-fold; firstly, AVP has an extremely short half-life in the 
circulation and secondly, AVP also activates V2 receptors that are linked to aquaporin-
mediated fluid reabsorption and concomitant elevation of blood pressure [42]. The present 
study was undertaken to directly overcome these drawbacks, through generation of 
enzymatically stable AVP peptides that possess a receptor activation profile more compelling 
to long-term benefits in obesity-diabetes.   
 Given the similarity in amino acid sequence of AVP and oxytocin [10], plus the 
established benefits of oxytocin receptor activation in diabetes [27], introduction of key 
oxytocin residues into the sequence of  AVP analogues might be envisaged to generate 
peptides with additional beneficial oxytocin receptor activation properties. However, it 
should be noted that oxytocin has a much less prolonged and diminished effect on insulin 
secretion than AVP as observed in this study and elsewhere [37], highlighting the major 
importance of V1a and V1b receptor activity for beta-cell actions. Interestingly, AVP is also 
believed to play a role in somatostatin secretion [43], indicating a complex mode of action on 
islet cells. Although it has been suggested that the stimulatory effects of AVP on insulin 
 
 
secretion are indirectly mediated by glucagon via paracrine islet interactions [20], we and 
others clearly show involvement of direct beta-cell stimulatory effects [12,18,39]. In 
agreement, we observed only moderate insulinotropic actions of the AVP analogues in clonal 
beta-cells, with much more prominent effects in isolated murine islets, confirming 
importance of paracrine islet cell signalling in this regard [20].  
In the current study, native AVP and some related analogues modulated both oxytocin 
and AVP receptor signalling pathways in BRIN BD11 cells, but preservation V2 receptor 
activity and associated effects on the kidney and fluid retention were not considered 
favourable. Interestingly, reduced AVP exhibited bioactivity at oxytocin, V1a and V1b , with 
no interaction at V2 receptors, but this peptide was relatively unstable. It should also be noted 
that removing the disulphide bridge appeared to lead to slightly different effects on insulin 
secretory activity of native AVP and Ac3IV. This is likely to reflect distinct changes in the 
three dimensional structure of the peptides and their interaction with receptors on target cells. 
However, further studies and detailed structure/function analysis are required to clarify this 
aspect. In addition, investigation of specific downstream signalling pathways would also have 
been useful to help further confirm receptor selectivity of the AVP analogues. However, on 
closer inspection, our in vitro characterisation data for 3IV, and the daughter analogue 
Ac3IV, led to selection of the N-terminally acetylated analogue to evaluate the potential 
benefits of combined V1a and V1b receptor signalling in diabetes. This included careful 
consideration of enzymatic stability, receptor activation prolife and in vitro bioactivity in 
both rodent and human beta-cells. Key in this decision was the lack of effect of Ac3IV on V2 
receptors and resistance to enzymatic degradation. In this regard, AVP is known to be rapidly 
degraded by vasopressinase enzymes in the circulation, as well as being subject to renal 
elimination [9]. Whilst our in vitro system suggests excellent enzymatic stability of Ac3IV, it 
did not assess the influence of kidney filtration on peptide bioactivity. To assist with more 
 
 
pragmatic quantification of the ability of Ac3IV to reverse metabolic dysregulation present in 
HFF mice, beneficial effects were compared directly against the approved antidiabetic drug, 
exendin-4. Importantly, there was no obvious change in mouse behaviour during, and gross 
tissue anatomy was unaltered at the end of, the Ac3IV treatment regimen suggesting lack of 
toxicity of this compound. Further longer-term studies are required to fully assess safety 
issues, but it is noteworthy that Ac3IV is structurally identical to native AVP barring addition 
of an N-terminal acetyl group and substitution of the third amino acid residue, phenylalanine 
for isoleucine, that already exists in the closely related peptide hormone oxytocin. 
Both peptide interventions decreased circulating glucose, body weight and fat content 
in HFF mice, presumable in part linked to prominent satiety actions. This is in full agreement 
with established metabolic benefits of GLP-1 receptor activation [2], and in harmony with 
actions of V1a receptor activation to suppress appetite [12]. Studies in mice pair-fed to mimic 
Ac3IV induced reductions of food intake would be required to help establish if benefits on 
body weight and metabolism occurred independently of changes in energy intake. Consistent 
with lack V2 action which might otherwise cause fluid retention, Ac3IV had only marginal 
effects on water intake with even a small cumulative increase being apparent towards the end 
of the study, but further studies are required to fully assess effects of Ac3IV on renal 
function. Somewhat surprisingly, given the established glucagonostatic effects of GLP-1 
receptor agonism [2] and reported glucagonotropic actions of AVP [20], circulating glucagon 
concentrations were reduced by Ac3IV, but not by exendin-4. This being in the face of 
increased pancreatic alpha-cell apoptotic rates in exendin-4 treated HFF mice, and a tendency 
for reduced pancreatic glucagon content. In relation to this, there was a reduction in islet- and 
beta-cell areas, as well as pancreatic insulin content, in both treatment groups of HFF mice, 
accompanied by decreased proliferation of both alpha- and beta-cells. Thus, changes in islet-
cell proliferation rates, or in recently reported islet cell transitioning events [44], probably 
 
 
outweigh decreased beta-cell apoptosis observed with both peptides. Moreover, GLP-1 
receptor signalling has recently been linked to positive effects on alpha- and beta-cell 
transdifferentaition [45]. Taken as a whole, it could be assumed that reductions in islet- and 
beta-cell areas are directly linked to the improved diabetic state evoked by both treatment 
regimens, leading to reduced metabolic demand.  
In keeping with this, circulating insulin concentrations were largely unaltered and 
peripheral insulin sensitivity significantly improved in peptide treated HFF mice, in 
accordance with notable GLP-1 and V1b receptor mediated benefits on insulin action [14,33]. 
Moreover, both Ac3IV and exendin-4 reduced total- and increased HDL-cholesterol levels. 
However, only Ac3IV significantly reduced circulating LDL-cholesterol and triglyceride 
levels, highlighting this as a distinct advantage over exendin-4 given that diabetes and obesity 
represent key risk factors for cardiovascular disease [46]. In addition, obesity-driven forms of 
diabetes are also associated with increased occurrence of bone fragility fractures [47,48], and 
both Ac3IV and exendin-4 augmenting bone mineral content and density, implying another 
potentially important therapeutic benefit.  
In spite of this, it should also be noted that increased levels of copeptin, a peptide co-
secreted with AVP and considered as an excellent surrogate marker for assessing circulating 
AVP concentrations [49], is associated with metabolic dysregulation and onset of diabetes 
[9]. However, this effect could well be linked to AVP receptor desensitisation and inherent 
adaptations to increase AVP secretion, and as such requires further detailed study. Indeed, a 
very similar phenomenon is reported for the incretin hormone GIP in type 2 diabetes [50] that 
possesses significant parallels with the bioactive profile of AVP, and this issue now appears 
to be more than surmountable from a therapeutic viewpoint [23]. Moreover, both oral and 
intraperitoneal glucose tolerance were substantially improved by Ac3IV in HFF mice, and 
consistently linked to the glucose-dependent insulinotropic actions. Such positive effects are 
 
 
particularly notable given aforementioned reductions in beta-cell area and pancreatic insulin 
content. Interestingly, AVP has been shown to stimulate V1b receptor-dependent secretion of 
GLP-1 from mouse and human intestines [51], and this could be one potential reason for the 
observed similar benefits of Ac3IV and exendin-4 on glucose disposal. Furthermore, we and 
others have previously illustrated similarities in beta-cell signalling pathways for AVP and 
the other hormones including incretin hormones [18]. However, further studies would be 
required to confirm the potential positive impact of Ac3IV on the secretion and action of 
GLP-1 and other gut hormones. 
In conclusion, combined sustained activation of V1a and V1b receptor pathways by 
Ac3IV exerts notable benefits on body weight and energy regulation, glucose homeostasis, 
insulin action and lipid metabolism, as well as reversing detrimental effects of high fat 
feeding on pancreatic architecture. Metabolic benefits were at least equivalent, and at times 
superior, to those exerted by the clinically approved GLP-1 mimetic, exendin-4. Future 
investigations into the therapeutic potential of AVP for the treatment of obesity and related 
diabetes may also want to consider further peptide optimisation and approaches capable of 
combining specific metabolic benefits of GLP-1 mimetics alongside V1a and V1b receptor 
activation. In this respect, it is not altogether uninteresting that effective strategies exist for 
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Replacement of amino acids in AVP with those from oxytocin in positions 3 and 8 are indicated in bold underlined text for each analogue. ˂ > indicates 
presence of the disulphide bridge between the two cysteines at position 1 and 6. To assess enzymatic stability, peptides (n=3) were incubated with plasma for 
4 h and degradation profile followed by RP-HPLC. For insulin secretory experiments, BRIN BD11 cells were incubated (n=8; 20 min) with peptides (10-6 M) 
in combination with 10-6 M of either selective oxytocin (OTRa, L-351,257), V1a (V1aRa , SR-49059), V1b (V1bRa , SR -149415) or V2 (V2Ra, Tolvaptan) 
receptor antagonists, and percentage inhibition of insulin secretion recorded. Values are expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 
compared with respective control. Abbreviations: Ac; acetyl. 
 
Peptide/ 
Analogues Sequence %  degradation at 4 h 
% reduction in insulin secretion compared to the control in the presence of 
receptor antagonists 
   OTRa V1aRa V1bRa V2Ra 
AVP C<YFQNC>PRG-NH2 100 ± 0.1 42 ± 5* 64 ± 3*** 57 ± 6*** 20 ± 10 
AVPR CYFQNCPRG-NH2 65 ± 0.4 59 ± 6** 42 ± 5* 39 ± 5 * 0 
Oxytocin C˂YIQNC>PLG-NH2 65 ± 0.9 42 ± 5* 15 ± 7 62 ± 4*** 1 ± 6 
8LV C<YFQNC>PLG-NH2 67 ± 0.1 42 ± 11* 46 ± 5*** 76 ± 5*** 92 ± 2*** 
8LVR CYFQNCPLG -NH2 88 ± 0.7 27 ± 20 8 ± 15 58 ± 5 ** 0 
3IV C<YIQNC>PRG-NH2 68 ± 0.2 68 ± 3*** 82 ± 3*** 45 ± 9* 22 ± 10 
3IVR CYIQNCPRG-NH2 64 ± 0.4 13 ± 5 34 ± 11* 46 ± 13* 0 
Ac3IV Ac-C<YIQNC>PRG-NH2 0 17 ± 4 24 ± 3*** 22 ± 5** 0 




Figure 1. Effects of AVP, oxytocin and AVP analogues Ac3IV, Ac3IVR on insulin 
secretion and receptor selectivity. (A-D) Effects of AVP and related analogues (10-12 - 10-6 
M) on insulin secretion (20 min) at (A,C) 5.6 and (B,D) 16.7 mM glucose from (A,B) rodent 
BRIN BD11 or (C,D) human 1.1B4 beta cells. (E) Isolated islets from male mice were 
incubated (60 min) at 16.7 mM glucose and the effects of AVP, oxytocin and Ac3IV (10-8 
and 10-6 M) on insulin secretion examined. (F) Effects of AVP and Ac3IV on insulin 
secretion (20 min) from oxytocin receptor KO INS1 832/13 beta-cells at 16.7 mM glucose. 
Values are mean ± SEM (A-D,F) n=8 and (E) n=3. *P<0.05, **P<0.01, ***P<0.001 
compared to respective glucose alone control. ΔP<0.05 compared to AVP at the same 
concentration. 
 
Figure 2. Effects of twice daily administration of Ac3IV or exendin-4 on (A) body 
weight, (B) total body fat, cumulative (C) energy and (D) fluid intake, as well as (E) 
glucose and (F) insulin concentrations in HFF mice. (A,C-F) Parameters were measured at 
regular intervals prior to, and during, 22 days twice-daily treatment with test peptides 
(25 nmol/kg bw) in HFF mice. (B) Parameter was measured on day 22. (E,F) Insets depict 
AUC data for glucose and insulin over the 22 day treatment period. All values are expressed 
as mean ± SEM for 7 mice. *P<0.05, **P<0.01, ***P<0.001 compared with HFF-saline 
control mice. 
 
Figure 3. Effects of twice daily administration of Ac3IV or exendin-4 on pancreatic 
circulating glucagon, hormone content, lipid profile and body composition in HFF mice. 
Parameters were measured after 22 days treatment with twice-daily injection of test peptides 
(25 nmol/kg bw) in HFF mice. (A) Plasma glucagon was determined using a commercially 
 
 
available ELISA kit. (B,C) Pancreatic tissue was isolated at the end of the study and (B) 
insulin or (C) glucagon content determined following acid-ethanol extraction. (D-G) 
Terminal non-fasted plasma (D) total cholesterol, (E) HDL-cholesterol (F) LDL-cholesterol 
and (G) triglycerides were measured by an ILab 650 Clinical Analyser. (H) Bone mineral 
density and (I) bone mineral content were measured by DXA. Values are mean ± SEM for 7 
mice. *P<0.05, **P<0.01 compared with HFF-saline control mice. 
 
Figure 4. Effects of twice daily administration of Ac3IV  or exendin-4 on glucose 
tolerance and insulin sensitivity in HFF mice. Parameters were measured after 22 days 
treatment with twice-daily injection of test peptides (25 nmol/kg bw) in HFF mice. (A,E) 
Blood glucose and (C,G) plasma insulin were measured prior to and after (A,C) i.p. or (E,G) 
oral administration of glucose alone (18 mmol/kg) at t = 0 min in 18 h fasted mice. (B,D,F,H) 
Respective AUC data for 0-120 min post glucose injection are shown. (I,J) Blood glucose 
was measured after i.p. administration of insulin (15 U/kg bw) at t = 0 min in non-fasted mice. 
(K) HOMA-IR was calculated using fasting insulin (mUI/L) multiplied by fasting glucose 
(mmol/L) divided by 22.5 on day 22. All values are expressed as mean ± SEM for 7 mice. 
*P<0.05, **P<0.01, ***P<0.001 compared with HFF-saline control mice. 
 
Figure 5. Effects of twice daily administration of Ac3IV or exendin-4 on pancreatic islet 
architecture as well as alpha- and beta cell proliferative and apoptotic rates in HFF 
mice. Parameters were measured after 22 days treatment with twice-daily injection of test 
peptides (25 nmol/kg bw) in HFF mice. (A) Representative images of islets showing insulin 
(red) and glucagon (green) immunoreactivity from each treatment group. (B-D) Islet 
architectural analysis included assessment of (B) total islet, (C) beta- and (D) alpha-cell 
areas. (E,G) Beta- and (F,H) alpha-cell proliferation or apoptotic rates were measured by co-
 
 
staining with insulin or glucagon, respectively, and (E,F) Ki-67 antibody or (G,H) TUNEL 
reagent, as appropriate. Values are mean ± SEM for 7 mice. *P<0.05, **P<0.01, ***P<0.001 
compared with HFF-saline control mice.  
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